Replies to post #202605 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Same author mentions the 18-2 ad comm vote against ADF labeling in separate article. I think it is earlier in May.

[Dante Fantasia]

Couldn't see the whole article as think one needs a subscription, but from what I could, was almost surely written by a long. A hopeful one.

NH is just real happy to play "keep quiet." No "hopeful" articles quoting him about the future or potential, no hype whatsoever. Quiet placement of industry giants like EP, and presentations given by an ex-Pfizer executive with strong ties to Canada. This is almost like the Manhattan Project--and we're sitting on a time bomb with very little time left on the trigger. All it comes down to is the ELI200 approval. If/Once approved, game over. The news will be all over the place, traders jumping in, and likely hedges with cash and no constraints jumping on, knowing cheaper now than if uplisted or bought out. Everything will come down to the modular nature of the sequestering of naltrexone getting out and a successful proof-of-concept...if those two events occur, which seems very likely, we are set to explode. There will be headlines about ELTP. Likely on all the investment rags. Real progress on widespread ADT's on opioids right now will shake the market.

Just my opinion, but no one can point to a single post and call me a "hyper" as I am very conservative as a long and very disinclined to do so. The window to major leveraging opportunity is quickly coming to an end. Then it's up big, and more with each approval (which may go faster now that sequestering proven) or a quick buyout. PFE just paid 5.2 billion for Anacor mainly for their frickin' eczema cream--that's still in P3 (as most of the rest of the line). What do you think a line of 15-17 ADT opioid just about all with first-to-market with an ADF will be worth once proof-of-concept attained? As an attractive as an a-topic dermatitis line and eczema treatment cream?

Again, I've talked myself into buying more later this week. A year in the .20's and .30's. This is going to be one of those "wish it were mine" type stocks...or could have but talked myself out of it by bashing ones.

We are just one acceptance away from the beginning of a very steep move to the upside (or big smack to the head if rejected--I just can't see what in the data/results would lead to a rejection), that in spite of OTC spinners and MM gaming, will only continue to keep moving upwards, until someone thinks it may be a good idea to pony up and buy us. Only a month and a half away.

Or sooner.

Getting stoked--GLTA,

Maz

[lasers]

$ELTP SequestOx FDA Approval moving along. Another day closer.


As for the article, This is a bias Long commentary as a SA Article and needs to be ignored. The FDA will decide on whether to take the advice of the ADCOM.